Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
The CDC defines severe obesity, or class III obesity, as any patient with a BMI of 40 or higher. TAVR among these patients is not associated with a lower survival rate, but it does lead to many more risks.
Heart teams can limit the risk of conduction disturbances that lead to permanent pacemaker implantation by utilizing both the cusp-overlap method and intracardiac echocardiography.
When patients with pacemakers die, what happens to the device? Typically, it ends up being discarded and forgotten—they were designed to be single-use devices, after all—but that does not have to be the case.
Researchers examined data from more than 21,000 patients treated from 1997 to 2018, publishing their findings in the Journal of the American Heart Association.
“Cardiothoracic imaging continues to evolve, fueled by technical innovations such as dynamic chest radiography, digital tomosynthesis and dark-field radiography," one radiologist said.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
